Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBP06 is an investigational microbiome-based live biotherapeutic product (LBP) developed by Shenzhen Xbiome Biotech for the treatment of respiratory diseases. Composed of a specific formulation of bacteria, LBP06 is designed to modulate the host's microbiota and immune responses, potentially through the gut-lung axis or direct interaction with the respiratory microbiome. The program is currently in the IND-enabling phase, progressing toward clinical evaluation to establish its safety and efficacy in managing respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LBP06.